Moderna Stock Plunges Despite Promising Melanoma Vaccine Results
Moderna's stock fell 17% despite positive Phase 3 trial results for its melanoma vaccine developed with Merck.
Moderna's stock fell 17% despite positive Phase 3 trial results for its melanoma vaccine developed with Merck. This is an original Token Times brief synthesising 2 outlets (The Crypto Basic, Blockonomi), with their figures cross-checked, plus live market data, as of Fri, 23 Oct 2026 15:00:02 UTC.
The significant reduction in melanoma recurrence and metastasis risk could transform cancer treatment, but investor reaction suggests concerns about the trial's early data release or other market factors.
- Moderna's melanoma vaccine reduced recurrence risk by 42% and metastasis risk by 38%.
- Two-year recurrence-free survival improved to 82.2% with the vaccine compared to 70% with Keytruda alone.
- Moderna's stock dropped 17% to $202.63 despite the positive trial results.
Multiple outlets, including The Crypto Basic and Blockonomi, report that Moderna stock fell 17% to $202.63 following the early release of its melanoma vaccine trial results. They agree that the treatment reduced melanoma recurrence or death risk by 42% and distant metastasis or death risk by 38% compared to Keytruda alone. However, Blockonomi provides the additional detail that two-year recurrence-free survival reached 82.2% with the combined treatment, compared to 70% for Keytruda alone.
- ImmunityBio Stock Falls Despite Promising Bladder Cancer Treatment Results
- Micron Stock Plunges 17% Despite $2,000 Price Target Forecast
- Moderna Stock Plunges Despite Promising Melanoma Vaccine Results — this brief
Moderna's stock experienced a significant decline of over 17% to $202.63 during Thursday's trading session, despite the release of promising Phase 3 trial results for its personalized melanoma vaccine, developed in collaboration with Merck.
The experimental vaccine, intismeran autogene, when combined with Merck's immunotherapy Keytruda, demonstrated a 42% reduction in the risk of cancer recurrence or death and a 38% reduction in the risk of distant metastasis or death compared to Keytruda alone. These results, which were published earlier than planned, indicate a substantial improvement in treatment efficacy.
The outlets agree on the core figures of the 42% and 38% risk reductions, as reported by The Crypto Basic and Blockonomi. However, Blockonomi provides the additional detail that two-year recurrence-free survival improved to 82.2% with the combined treatment, compared to 70% for Keytruda alone.
The development of this vaccine could have significant implications for cancer treatment, potentially improving survival rates and reducing the risk of metastasis. However, the market's negative reaction, despite the positive clinical outcomes, suggests that investors may be concerned about the early release of the data or other factors.
In the broader market context, the total crypto market cap stands at $2.81 trillion, with the overall market remaining relatively flat. 
Bitcoin has seen a modest 0.07% increase in the last 24 hours, and the Fear & Greed Index is at 50, indicating a neutral sentiment.
3 key figures independently matched across 2 outlets reporting this story.
Token Times extracts the figures each outlet reports and flags the ones that agree. Numbers cited by only one outlet are attributed in the brief, not shown as corroborated.
Figures and sectors in this story, checked live against on-chain aggregators · October 23, 2026.
Token Times reads these figures directly from on-chain aggregators (DeFiLlama, mempool.space) at build time — independent of what any outlet reported. Sector totals aggregate every protocol DeFiLlama tracks in that category. Values are live and will change.
Moderna Stock Plunges Despite Promising Melanoma Vaccine Res — questions & answers
Why did Moderna stock drop despite positive trial results?
The stock drop may be due to the early release of trial data or other market factors, despite the positive clinical outcomes.
What are the key results of the melanoma vaccine trial?
The vaccine reduced melanoma recurrence risk by 42% and metastasis risk by 38% compared to Keytruda alone.
How did the combined treatment affect two-year recurrence-free survival?
Two-year recurrence-free survival reached 82.2% with the combined treatment, compared to 70% for Keytruda alone.
Which outlets reported this story?
This is an original Token Times brief that synthesises reporting from The Crypto Basic, Blockonomi, with the key figures cross-checked for agreement across them. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original Token Times brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.